康方生物完成一般授权配售：2000万股新股以97.76港元发行，净募资约19.41亿港元

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited
take no responsibility for the contents of this announcement, make no representation as to
its accuracy or completeness and expressly disclaim any liability whatsoever for any loss
howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
This announcement is for information purposes only and does not constitute an invitation or
offer to acquire, purchase or subscribe for securities of the Company.
Neither this announcement nor any copy thereof may be released into or distributed directly
or indirectly in the United States or any other jurisdiction where such release or distribution
might be unlawful.
This announcement does not constitute or form a part of any offer or solicitation to
purchase or subscribe for securities in the United States. The securities mentioned herein
have not been, and will not be, registered under the United States Securities Act of 1933
(the ‘‘U.S. Securities Act’’), and may not be offered or sold in the United States unless
registered under the U.S. Securities Act or pursuant to an exemption from, or in a
transaction not subject to, registration under the U.S. Securities Act. The Company has no
intention to register under the U.S. Securities Act any of the securities referred to herein or
to conduct a public offering of securities in the United States.

Akeso, Inc.
康 方 生 物 科 技（ 開 曼 ）有 限 公 司
(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926))

COMPLETION OF PLACING OF NEW SHARES
UNDER GENERAL MANDATE
Sole Overall Coordinator, Sole Global Coordinator and Sole Bookrunner

Reference is made to the announcement of Akeso, Inc. (the ‘‘Company’’) dated October 14,
2026 in respect of the proposed placing of new Shares under general mandate (the
‘‘Announcement’’). Unless otherwise stated, the terms used in this announcement shall have
the same meaning as defined in the Announcement.

–1–

COMPLETION OF THE PLACING
The Board is pleased to announce that the condition to the Placing Agreement has been
fulfilled and completion of the Placing took place on October 16, 2026. An aggregate of
20,000,000 Placing Shares have been placed by the Placing Agent to not less than six
Placees at the Placing Price of HK$97.76 per Placing Share pursuant to the terms and
conditions of the Placing Agreement, representing approximately 2.13% of the issued share
capital of the Company as enlarged by the allotment and issue of the Placing Shares
immediately upon completion of the Placing.
To the best of the Directors’ knowledge, information and belief, having made all reasonable
enquiries, the Placees and their respective ultimate beneficial owners are professional,
institutional, or other investors who are third parties independent of the Company and its
connected persons.
The Company received net proceeds from the Placing, after deducting the placing
commission and other related expenses and professional fees, of approximately
HK$1,940.98 million. The Company intends to use the net proceeds for the purposes as
disclosed in the section headed ‘‘Reasons for the Placing and Use of Proceeds’’ in the
Announcement.
SHAREHOLDING STRUCTURE OF THE COMPANY BOTH IMMEDIATELY
BEFORE AND UPON COMPLETION OF THE PLACING
The table below sets out the shareholding structure of the Company both immediately before
and upon completion of the Placing.
Immediately before completion
of the Placing
Approximate %
Number of of total Shares
Shares held
in issue
Dr. XIA Yu and corporations controlled
by her(1)
Dr. LI Baiyong and corporation
controlled by him(2)
Dr. WANG Zhongmin Maxwell and
corporation controlled by him(3)
Dr. ZHANG Peng and corporation
controlled by him(4)
The Placees
Other public Shareholders
Total

Immediately upon completion
of the Placing
Approximate %
Number of of total Shares
Shares held
in issue

100,982,871

10.96%

100,982,871

10.73%

49,173,194

5.34%

49,173,194

5.22%

42,799,323

4.65%

42,799,323

4.55%

32,318,065
—
695,869,723

3.51%
—
75.54%

32,318,065
20,000,000
695,869,723

3.43%
2.13%
73.94%

921,143,176

100.00%

941,143,176

100.00%

–2–

Notes:
(1)

Dr. XIA Yu is the chairwoman of the Board and an executive Director, and holds such Shares
beneficially and through (a) Golden Oaks LLC, an entity wholly owned by Dr. XIA; and (b) Aquae
Hyperion Limited, with Zedra Trust Company (Cayman) Limited as the trustee and Dr. XIA as the
enforcer.

(2)

Dr. LI Baiyong is an executive Director and holds such Shares beneficially and through Kampfire LLC,
an entity wholly owned by Dr. LI.

(3)

Dr. WANG Zhongmin Maxwell is an executive Director and holds such Shares beneficially and through
Blazing Rosewood LLC, an entity wholly owned by Dr. WANG.

(4)

Dr. ZHANG Peng is an executive Director and holds such Shares through Waterband Limited with
Cantrust (Fareast) Limited as the trustee and Dr. ZHANG as the settlor.

By Order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive Director
Hong Kong, October 16, 2026
As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and
executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as
executive Directors, Mr. XIE Ronggang as non-executive Director, and Dr. ZENG Junwen,
Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.

–3–